Slingshot members are tracking this event:
Ionis Pharma (IONS) to report on Phase 3 study of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy in the summer of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
The United States Food and Drug Administration granted orphan drug status and fast track designation to ISIS-SMNRx for the treatment of patients with SMA.
Slingshot Insights Explained
Apr 24, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Sma, Spinal Muscular Atrophy, Muscular Dystrophy, Phase 3 Study, Ionis-smn Rx, Isis 396443